![Japanese Prime Minister Yoshihide Suga [사진=AP 연합뉴스]](https://i0.wp.com/img.hankyung.com/photo/202102/01.25435525.1.jpg?w=560&ssl=1)
Japanese Prime Minister Yoshihide Suga [사진=AP 연합뉴스]
It was found that Japan, which had discarded some of the supplies because it was unable to secure a special syringe even after preparing the vaccine, made a request for bulk purchase from a Korean syringe company. This company is known as a company that has been recognized for its technological prowess enough to encourage President Moon Jae-in to visit.
Kyodo News Agency reported on the 18th that the Japanese government has ordered 80 million units from Poonglim Pharmatech, a special syringe manufacturer in Korea.
Previously, Japan signed a contract with Pfizer-Bioentech to supply 72 million vaccines (144 million doses) based on six doses per bottle. However, the general syringe used by Japan can only be inoculated 5 times per bottle due to the large amount of vaccine that remains in the syringe after administration. If a special syringe is not available, the vaccine cannot be supplied.
In order to solve this problem, the Japanese government has requested the Osaka-based medical device manufacturer Nipro to increase the production of special syringes. Nipro plans to increase its monthly production at its plant in Thailand several times from the existing 500,000 units, but supply of increased production is expected to be possible only in September of this year. .
Poonglim Pharmatech has received more than 260 million orders from 20 countries and decided to increase its monthly production from 10 million to 20 million from next month.
President Moon Jae-in also visited the headquarters of Poonglim Pharmatech, located in Gunsan Free Trade Zone in Osikdo-dong, Jeollabuk-do, to encourage researchers and workers. President Moon Jae-in praised his hard work at this meeting, saying, “Following the diagnosis kit, we have shown the excellence of K-quarantine once again” regarding the minimum residual type injector to be used for the corona 19 vaccination.
![On the afternoon of the 18th, President Moon Jae-in is demonstrating a comparison between a general syringe and a minimum residual type syringe at Poonglim Pharmatech, a production facility for the least residual type (LDS) syringe for corona 19 vaccination in Gunsan, Jeollabuk-do. 2021.2.18 [사진=연합뉴스]](https://i0.wp.com/img.hankyung.com/photo/202102/01.25435526.1.jpg?w=560&ssl=1)
On the afternoon of the 18th, President Moon Jae-in is demonstrating a comparison between a general syringe and a minimum residual type syringe at Poonglim Pharmatech, a production facility for the least residual type (LDS) syringe for corona 19 vaccination in Gunsan, Jeollabuk-do. 2021.2.18 [사진=연합뉴스]
Reporter Kang Kyung-joo [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution